Using intratumoral immunotherapy to improve immune responses in breast cancer
Intratumoral immunotherapy to enhance T cell infiltration and augment immune checkpoint blockade responses across molecular subtypes of breast cancer
This study is exploring a new way to treat advanced breast cancer by using a special therapy that helps your immune system's T cells better attack the tumors, with the goal of making them more responsive to other treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10914129 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating breast cancer by using intratumoral immunotherapy to enhance the infiltration of T cells into tumors. The study focuses on patients with advanced, recurrent, or metastatic breast cancer, aiming to convert poorly immunogenic tumors into highly inflamed lesions that can respond better to immune checkpoint inhibitors. By analyzing the immune response at a cellular level, the research seeks to identify how specific immune pathways can be activated to improve treatment outcomes across different molecular subtypes of breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced, recurrent, or metastatic breast cancer, particularly those with low T cell infiltration in their tumors.
Not a fit: Patients with early-stage breast cancer or those whose tumors are already highly responsive to existing immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that enhances the effectiveness of existing immunotherapies for breast cancer patients.
How similar studies have performed: Previous research has shown promising results using similar intratumoral immunotherapy approaches to enhance immune responses in various cancers, indicating potential for success in this study.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Crosby, Erika J — Duke University
- Study coordinator: Crosby, Erika J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.